| Literature DB >> 36079919 |
Ting Xu1, Shanshan Hu1, Yan Liu1, Kang Sun1, Liyong Luo1, Liang Zeng1.
Abstract
Hawk tea (Litsea coreana Levl. var. lanuginosa) is a traditional herbal tea in southwestern China, and was found to possess hepatoprotective effects in our previous study. However, it is unclear whether hawk tea flavonoids (HTF) can alleviate alcoholic liver damage (ALD). Firstly, we extracted and identified the presence of 191 molecules categorized as HTFs, with reynoutrin, avicularin, guaijaverin, cynaroside, and kaempferol-7-O-glucoside being the most prevalent. After taking bioavailability into consideration and conducting comprehensive sorting, the contribution of guaijaverin was the highest (0.016 mg/mice). Then, by daily intragastric administration of HTF (100 mg/kg/day) to the ALD mice, we found that HTF alleviated liver lipid deposition (inhibition of TG, TC, LDL-C) by reducing liver oxidative-stress-mediated inflammation (up-regulation NRF2/HO-1 and down-regulation TLR4/MyD88/NF-κB pathway) and reshaping the gut microbiota (Lactobacillus, Bifidobacterium, Bacillus increased). Overall, we found HTF could be a potential protective natural compound for treating ALD via the gut-liver axis and guaijaverin might be the key substance involved.Entities:
Keywords: alcoholic liver damage; antioxidant; guaijaverin; hawk tea; inflammatory reaction; intestinal flora
Mesh:
Substances:
Year: 2022 PMID: 36079919 PMCID: PMC9459715 DOI: 10.3390/nu14173662
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Figure 1Flavonoids in hawk tea. (a) Extraction method of hawk tea flavonoids. (b) The DPPH radical quenched percentage of HTF before and after purification. (c) Qualification of HTF composition. HTF: hawk tea flavonoids; VC: vitamin C.
Figure 2HTF reduced alcohol-induced oxidative stress and inflammatory response in acute ALD-model mice. (a) The experimental group. (b)Body weight. (c) Level of ADH. (d) Level of ALDH. (e) Level of MDA. (f) Level of GSH. (g) Level of SOD. (h) Level of interleukin-6 (IL-6). (i) Level of interleukin-1(IL-1β). (j) Level of TNF-α. (k) Western blot. (l) Western blot. (m) Western blot analysis (n = 3 per group). Data are mean ± SEM. Significance was determined by one-way ANOVA corrected for multiple comparisons with Dunnett’s test. # p < 0.05 and ## p < 0.01 compared with Alcohol group. ns, p > 0.05, * p < 0.05 and ** p < 0.01 compared with other HTF group.
Compounds in HTF which Related to Hepatoprotection, their content and biological effects.
| CAS | Components | Content | Outcomes and Potential Molecular Mechanisms | Biological Activities | OB | DL | Contribution (mg) | Ref. |
|---|---|---|---|---|---|---|---|---|
| 22255-13-6 | Quercetin-3-O-arabinoside (Guaijaverin) * | 2.72 | Reduction in the levels of IL-1β, IL-18, and Caspase-1 inhibits the expression of P62 and Pink1; inhibition of MAPK and PI3K/Akt signaling pathways | Antioxidant and anti-inflammatory | 29.65 | 0.7 | 0.016 | [ |
| 23627-87-4 | Kaempferol-3-O-galactoside (Trifolin) | 2.05 | Activation of aldehyde dehydrogenase; radical-scavenging activity | Antioxidant and hepatoprotective activity | 19.61 | 0.74 | 0.008 | [ |
| 490-46-0 | Epicatechin | 1.16 | Amelioration of high circulating levels of lipids and endotoxins, and mitigates systemic inflammation; ease Hepatic dysregulation of lipid metabolism; inhibition of SCAP and prevents the activation of SREBP-1c | Ease hepatic dysregulation of lipid metabolism | 28.93 | 0.24 | 0.007 | [ |
| 117-39-5 | Quercetin | 0.51 | Reduction in the levels of TNF-α; inhibition of the lipoxygenase and cyclooxygenase pathways | Anti-inflammatory | 46.43 | 0.28 | 0.005 | [ |
| 20315-25-7 | Procyanidin B2 | 0.31 | Proliferation inhibited and apoptosis induced in HSCs; down-regulate the expressions of VEGF-A, HIF-1α, α-SMA, Col-1 and TGF-β1 of HSCs | Hepatoprotective effect and anti-inflammatory | 67.87 | 0.66 | 0.004 | [ |
| 480-18-2 | Dihydroquercetin (Taxifolin) | 0.34 | Inhibit the expression of P2X7R, IL-1β, and caspase-1; exhibit an inhibitory effect on lipid accumulation | Hepatoprotective effect and anti-inflammatory | 57.84 | 0.27 | 0.004 | [ |
| 5373-11-5 | Luteolin-7-O-glucoside (Cynaroside) | 2.60 | Inhibited HMGB1/TLR4/NF-κB/MAPKs signaling pathways | Antioxidant | 7.29 | 0.78 | 0.004 | [ |
| 154-23-4 | Catechin | 0.46 | Superoxide anion and superoxide-scavenging activity; suppress inflammation-related signal expression, including TNFA, COX-2, and iNOS | Antioxidant and anti-inflammatory | 29.86 | 0.02 | 0.003 | [ |
| 549-32-6 | Quercetin-3-O-xyloside (Reynoutrin) | 5.06 | Inhibit the transcriptional activity of nuclear factor kappa-B | Antioxidant | 1.68 | 0.7 | 0.002 | [ |
| 17650-84-9 | Kaempferol-3-O-rutinoside (Nicotiflorin) | 2.08 | Reduce the levels of IL-1β, IL-6, TNF-α, IFN-γ; decreased the MDA levels; increase GSH and the SOD activity; decrease the AST, ALT level | Hepatoprotective effect | 3.64 | 0.73 | 0.002 | [ |
| 572-30-5 | Avicularin (Quercetin-3-O-α-L-arabinofuranoside) | 3.47 | A high radical-scavenging activity | Hepatoprotective effect | 2.06 | 0.7 | 0.001 | [ |
| 16290-07-6 | Kaempferol-7-O-glucoside | 2.21 | NF-κB inhibitor | Antioxidant, anti-inflammatory and hepatoprotective activity | 41.88 | 0.24 | 0.001 | [ |
| 520-18-3 | Kaempferol (3,5,7,4′-Tetrahydroxyflavone) | 0.14 | NF-κB inhibitor | Antioxidant, anti-inflammatory and hepatoprotective activity | 41.88 | 0.24 | 0.001 | [ |
| 480-41-1 | Naringenin (5,7,4′-Trihydroxyflavanone) | 0.10 | Decreased levels of plasma and tissue total cholesterol; inhibition of oxidative stress through TGF-β pathway and prevention of the trans-differentiation of hepatic stellate cells (HSC). Pro-apoptotic effect, inhibition of MAPK, TLR, VEGF, and TGF-β, modulation of lipids and cholesterol synthesis, triglycerides, free fatty acids, HMG CoA reductase and collagen content | Hepatoprotective effect and anti-inflammatory | 42.36 | 0.21 | 0.001 | [ |
| 491-50-9 | Quercetin-7-O-glucoside | 1.31 | Reduction in the levels of TNF-α, inhibition of COX2 and iNOS protein expression, inhibition of cow milk xanthine oxidase | Hepatoprotective effect | 2.85 | 0.79 | 0.001 | [ |
| 480-20-6 | Aromadendrin (Dihydrokaempferol) | 0.11 | Regulation of the Keap1/Nrf2 pathway and regulate oxidative stress | Ameliorates severe acute pancreatitis | 24.15 | 0.24 | 0.001 | [ |
| 99882-10-7 | Kaempferol-3-O-arabinoside | 1.14 | Antioxidant and anti-apoptotic properties, increase GSH and the SOD activity, decrease the AST, ALT level | Hepatoprotective effect | 2.73 | 0.65 | 0.001 | [ |
| 19833-12-6 | Myricetin-3-O-glucoside | 1.38 | increase GSH and the SOD activity, decrease the AST, ALT level | Hepatoprotective effect | 1.43 | 0.79 | 0.000 | [ |
| 28608-75-5 | Luteolin-8-C-glucoside (Orientin) | 0.87 | Inhibition of LPS-induced hyperpermeability in HUVEC cells | Anti-inflammatory | 1.79 | 0.75 | 0.000 | [ |
| 571-74-4 | Sexangularetin | 0.02 | Decrease in the inflammatory markers IL-1β and myeloperoxidase | Anti-inflammatory | 62.86 | 0.3 | 0.000 | [ |
| 153-18-4 | Rutin | 0.11 | Lower triglyceride content and abundance of lipid droplets; reduce cellular malondialdehyde level and restore superoxide dismutase activity in hepatocytes; suppress TGF-β/Smad signaling pathway | Hepatoprotective effect; dysfunctions of lipid metabolism | 3.2 | 0.68 | 0.000 | [ |
| 520-36-5 | Apigenin | 0.01 | Inhibition of PI3K/Akt/mTOR pathway; activate the SIRT1 pathway; inhibit hepatic stellate cell activation and autophagy via TGF-β 1/Smad3 and p38/PPAR α Pathways | Hepatoprotective effect | 23.06 | 0.21 | 0.000 | [ |
| 124027-51-6 | Quercetin-3-O-(6″-acetyl)galactoside | 1.89 | NI | NI | NI | NI | - | [ |
| 52525-35-6 | Quercetin-3-O-robinobioside | 1.00 | Reactive oxygen species scavenging activity | Hepatoprotective effect | NI | NI | - | [ |
| 47705-70-4 | Cyanidin-3-O-glucoside (Kuromanin) | 0.52 | Reduction in the levels of IL-1β, IL-6; activate mitophagy via the PINK1-PARKIN signaling pathway | Anti-inflammatory | NI | NI | - | [ |
OB, oral bioavailability; DL, drug-likeness; NI: no information has been found; *, we speculated it might to be the key substance which could alleviate acute liver damage.
Figure 3HTF reduced alcohol-induced lipid deposition in the liver. (a) Hepatic TC level. (b) Hepatic TG level. (c) Hepatic LDL-C level. (d) Hepatic HDL-C level. (e) Serum ALT level. (f) Serum AST level. (g) Percentage of lipid droplet area. (h) Histological examination of liver tissues. (i) The Oil Red O staining slice. Data are mean ± SEM. Significance was determined by one-way ANOVA corrected for multiple comparisons with Dunnett’s test. # p < 0.05 and ## p < 0.01 compared with alcohol group. ns, p > 0.05, * p < 0.05 and ** p < 0.01 compared with other HTF group.
Figure 4HTF reshaped the gut microbiota in alcohol-induced mice. (a) α-Diversity representing the Ace index at the ASV level. (b) PCoA plot of the gut microbiota based on weighted UniFrac matrixes. (c) Typing analysis of the phylum level in different treatment groups. (d) The Firmicutes/Bacteroidetes ratio of all groups. (e) Analysis of gut microbiota composition at the phylum level. (f) Relative abundance of the fecal microbiota with relative abundance greater than 1% at the phylum level. (g) Analysis of gut microbiota composition at the genus level. (h) Indicator bacteria of intestinal microbiota with LDA scores of 2 or greater in mice with different treatments. Data are mean ± SEM (n = 5 per group). * p < 0.05, ** p < 0.01 vs. the alcohol group.
Figure 5Correlation analysis. (a) Community heatmap analysis at the genus level. The color was defined at the phylum level. The x-axis was the sample name. (b) Pearson correlation between gut microbiota and metabolic factors at the genus level. * p < 0.05, ** p < 0.01, and *** p < 0.005.